Results 121 to 130 of about 5,421 (159)

Sulbactam-durlobactam treatment for pulmonary infections caused by carbapenem-resistant Acinetobacter baumannii in lung transplant recipients

Journal of Infection
Piaopiao Zhang, Jing Wu, Yongshan Xu, Huqiang Wan, Jingyu Chen, Man Huang   +5 more
openaire   +2 more sources

Clinico-Microbiological Profile of Carbapenem-Resistant Acinetobacter baumannii Isolates From Intensive Care Unit Patients and In Vitro Activity of Sulbactam-Durlobactam: A Cross-Sectional Study From Eastern India. [PDF]

Cureus
Susanna A, Singh N, Verma G, Mohapatra I, Pradhan S, Panda SS, Prince B, Pattnaik D, Mishra PP.   +8 more
europepmc   +1 more source

Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review. [PDF]

Infection
Karakonstantis S, Ioannou P, Kofteridis DP.   +2 more
europepmc   +1 more source

<i>Ex vivo</i> assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations. [PDF]

Antimicrob Agents Chemother
Abouelhassan Y, Shen Y, Chen A, Ye X, Nicolau DP, Kuti JL.   +5 more
europepmc   +1 more source

A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of <i>Acinetobacter</i> spp. [PDF]

Antimicrob Agents Chemother
Veeraraghavan B, Shin E, Bakthavatchalam YD, Manesh A, Dubey D, Tascini C, Taracila MA, Hujer AM, Jacobs MR, Bonomo RA.   +9 more
europepmc   +1 more source